{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:21:32Z","timestamp":1788484892237,"version":"build-2803163510"},"reference-count":110,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Card Fail Rev"],"abstract":"<jats:p>Hypertrophic cardiomyopathy is a prevalent condition characterised by ventricular hypertrophy, which results in left ventricular outflow obstruction in two-thirds of patients. Traditional pharmacological therapies, including \u03b2-blockers, calcium channel blockers and disopyramide, have been the cornerstone of symptom management but lack disease-modifying effects. The introduction of cardiac myosin inhibitors as the first therapy to directly target sarcomeric hypercontractility has dramatically changed clinical practice. However, several logistical factors presently limit the widespread adoption of cardiac myosin inhibitors, and their long-term side effects and outcomes require ongoing investigation. Emerging pharmacological approaches, including EDG-7500 and gene therapies, aim to refine treatment strategies. For patients with refractory symptoms, invasive septal reduction therapies, including surgical myectomy and alcohol septal ablation, remain critical. Innovations such as radiofrequency ablation and septal scoring along the midline endocardium (SESAME) offer promising, minimally invasive alternatives. As treatment options expand, optimising patient selection, monitoring protocols and long-term outcomes remain essential to advancing care for patients with obstructive hypertrophic cardiomyopathy.<\/jats:p>","DOI":"10.15420\/cfr.2025.08","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:22:15Z","timestamp":1762251735000},"source":"Crossref","is-referenced-by-count":4,"title":["Emerging Pharmacological and Invasive Therapies for Hypertrophic Cardiomyopathy with Obstructive Physiology"],"prefix":"10.15420","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5119-7120","authenticated-orcid":false,"given":"Emily Li-Wen","family":"Chu","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, CA, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2971-1909","authenticated-orcid":false,"given":"Daniel Seung","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, CA, US; Wu Tsai Human Performance Alliance, Stanford University, Stanford, CA, US; Cardiovascular Institute, Stanford University, Stanford, CA, US; Center for Digital Health, Stanford University, Stanford, CA, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-6526","authenticated-orcid":false,"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Oregon Health & Science University, Portland, OR, US; Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, US"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"ref0","unstructured":"Ommen SR, Ho CY, Asif IM, et al. 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines. J Am Coll Cardiol 2024;83:2324\u20132405. https:\/\/doi.org\/10.1016\/j.jacc.2024.02.014; PMID:\u00a038727647."},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Harper AR, Goel A, Grace C, et al. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. Nat Genet 2021;53:135\u201342. https:\/\/doi.org\/10.1038\/s41588-020-00764-0; PMID:\u00a033495597.","DOI":"10.1038\/s41588-020-00764-0"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 2017;121:749\u201370. https:\/\/doi.org\/10.1161\/circresaha.117.311059; PMID:\u00a028912181.","DOI":"10.1161\/circresaha.117.311059"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Anderson RL, Trivedi DV, Sarkar SS, et al. Deciphering the super relaxed state of human \u03b2-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. Proc Natl Acad Sci U S A 2018;115:E8143\u201352. https:\/\/doi.org\/10.1073\/pnas.1809540115; PMID:\u00a030104387.","DOI":"10.1073\/pnas.1809540115"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Lehman SJ, Crocini C, Leinwand LA. Targeting the sarcomere in inherited cardiomyopathies. Nat Rev Cardiol 2022;19:353\u201363. https:\/\/doi.org\/10.1038\/s41569-022-00682-0; PMID:\u00a035304599.","DOI":"10.1038\/s41569-022-00682-0"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Desai MY, Hajj-Ali A, Rutkowski K, et al. Real-world experience with mavacamten in obstructive hypertrophic cardiomyopathy: observations from a tertiary care center. Prog Cardiovasc Dis 2024;86:62\u20138. https:\/\/doi.org\/10.1016\/j.pcad.2024.02.001; PMID:\u00a038354765.","DOI":"10.1016\/j.pcad.2024.02.001"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Kim DS, Chu EL, Keamy-Minor EE, et al. One-year real-world experience with mavacamten and its physiologic effects on obstructive hypertrophic cardiomyopathy. Front Cardiovasc Med 2024;11:1429230. https:\/\/doi.org\/10.3389\/fcvm.2024.1429230; PMID:\u00a039314763.","DOI":"10.3389\/fcvm.2024.1429230"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Baker JG, Kemp P, March J, et al. Predicting in vivo cardiovascular properties of \u03b2-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses. FASEB J 2011;25:4486\u201397. https:\/\/doi.org\/10.1096\/fj.11-192435; PMID:\u00a021865315.","DOI":"10.1096\/fj.11-192435"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Shah K, Seeley S, Schulz C, et al. Calcium channels in the heart: disease states and drugs. Cells 2022;11:943. https:\/\/doi.org\/10.3390\/cells11060943; PMID:\u00a035326393.","DOI":"10.3390\/cells11060943"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Toshima H, Koga Y, Nagata H, et al. Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. Double-blind crossover study. Jpn Heart J 1986;27:701\u201315. https:\/\/doi.org\/10.1536\/ihj.27.701; PMID:\u00a03546779.","DOI":"10.1536\/ihj.27.701"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Taha M, Dahat P, Toriola S, et al. Metoprolol or verapamil in the management of patients with hypertrophic cardiomyopathy: a systematic review. Cureus 2023;15:e43197. https:\/\/doi.org\/10.7759\/cureus.43197; PMID:\u00a037565181.","DOI":"10.7759\/cureus.43197"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Rosing DR, Kent KM, Maron BJ, Epstein SE. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. Circulation 1979;60:1208\u201313. https:\/\/doi.org\/10.1378\/chest.78.1_supplement.239; PMID:\u00a06995039.","DOI":"10.1378\/chest.78.1_supplement.239"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Frank MJ, Abdulla AM, Watkins LO, et al. Long-term medical management of hypertrophic cardiomyopathy: usefulness of propranolol. Eur Heart J 1983;4(Suppl F):155\u201364. https:\/\/doi.org\/10.1093\/eurheartj\/4.suppl_f.155; PMID:\u00a06686531.","DOI":"10.1093\/eurheartj\/4.suppl_f.155"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Dybro AM, Rasmussen TB, Nielsen RR, et al. Randomized trial of metoprolol in patients with obstructive hypertrophic\u00a0cardiomyopathy. J Am Coll Cardiol 2021;78:2505\u201317. https:\/\/doi.org\/10.1016\/j.jacc.2021.07.065; PMID:\u00a034915981.","DOI":"10.1016\/j.jacc.2021.07.065"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Dybro AM, Rasmussen TB, Nielsen RR, et al. Metoprolol improves left ventricular longitudinal strain at rest and during exercise in obstructive hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2023;36:196\u2013204. https:\/\/doi.org\/10.1016\/j.echo.2022.09.008; PMID:\u00a036444740.","DOI":"10.1016\/j.echo.2022.09.008"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Dybro AM, Rasmussen TB, Nielsen RR, et al. Effects of metoprolol on exercise hemodynamics in patients with obstructive hypertrophic\u00a0cardiomyopathy. J Am Coll Cardiol 2022;79:1565\u201375. https:\/\/doi.org\/10.1016\/j.jacc.2022.02.024; PMID:\u00a035450573.","DOI":"10.1016\/j.jacc.2022.02.024"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Bonow RO, Rosing DR, Bacharach SL, et al. Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy. Circulation 1981;64:787\u201396. https:\/\/doi.org\/10.1161\/01.cir.64.4.787; PMID:\u00a07196813.","DOI":"10.1161\/01.cir.64.4.787"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Pinto G, Chiarito M, Puscas T, et al. Comparative influences of beta blockers and verapamil on cardiac outcomes in hypertrophic cardiomyopathy. Am J Cardiol 2025;235:9\u201315. https:\/\/doi.org\/10.1016\/j.amjcard.2024.10.029; PMID:\u00a039477199.","DOI":"10.1016\/j.amjcard.2024.10.029"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Gilligan DM, Chan WL, Joshi J, et al. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. J Am Coll Cardiol 1993;21:1672\u20139. https:\/\/doi.org\/10.1016\/0735-1097(93)90386-f; PMID:\u00a08496536.","DOI":"10.1016\/0735-1097(93)90386-F"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Coppini R, Ferrantini C, Pioner JM, et al. Electrophysiological and contractile effects of disopyramide in patients with obstructive hypertrophic cardiomyopathy: a\u00a0translational study. JACC Basic Transl Sci 2019;4:795\u2013813. https:\/\/doi.org\/10.1016\/j.jacbts.2019.06.004; PMID:\u00a031998849.","DOI":"10.1016\/j.jacbts.2019.06.004"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Sherrid MV, Barac I, McKenna WJ, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;45:1251\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2005.01.012; PMID:\u00a015837258.","DOI":"10.1016\/j.jacc.2005.01.012"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Adler A, Fourey D, Weissler-Snir A, et al. Safety of outpatient initiation of disopyramide for obstructive hypertrophic cardiomyopathy patients. J Am Heart Assoc 2017;6:e005152. https:\/\/doi.org\/10.1161\/jaha.116.005152; PMID:\u00a028550094.","DOI":"10.1161\/jaha.116.005152"},{"key":"ref22","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020;396:759\u201369. https:\/\/doi.org\/10.1016\/s0140-6736(20)31792-x; PMID:\u00a032871100."},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Cremer PC, Geske JB, Owens A, et al. Myosin inhibition and left ventricular diastolic function in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: insights from the VALOR-HCM study. Circ Cardiovasc Imaging 2022;15:e014986. https:\/\/doi.org\/10.1161\/circimaging.122.014986; PMID:\u00a036335645.","DOI":"10.1161\/circimaging.122.014986"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Rader F, Or\u0119ziak A, Choudhury L, et al. Mavacamten treatment for symptomatic\u00a0obstructive hypertrophic\u00a0cardiomyopathy: interim results from the MAVA-LTE study, EXPLORER-LTE cohort. JACC Heart Fail 2024;12:164\u201377. https:\/\/doi.org\/10.1016\/j.jchf.2023.09.028; PMID:\u00a038176782.","DOI":"10.1016\/j.jchf.2023.09.028"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Desai MY, Wolski K, Owens A, et al. Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 128 results from VALOR-HCM. Circulation 2025;151:1378\u201390. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.072445; PMID:\u00a039556124.","DOI":"10.1161\/circulationaha.124.072445"},{"key":"ref26","unstructured":"Maron MS, Masri A, Nassif ME, et al. Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. N Engl J Med 2024;390:1849\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2401424; PMID:\u00a038739079."},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Grillo MP, Erve JCL, Dick R, et al. In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin. Xenobiotica 2019;49:718\u201333. https:\/\/doi.org\/10.1080\/00498254.2018.1495856; PMID:\u00a030044681.","DOI":"10.1080\/00498254.2018.1495856"},{"key":"ref28","unstructured":"Bristol-Myers Squibb. Camzyos\u2122 (mavacamten) capsules. 2024. https:\/\/www.camzyoshcp.com (accessed 15 January 2025)."},{"key":"ref29","unstructured":"Bristol-Myers Squibb. CAMZYOS\u00ae (mavacamten) capsules for oral use. [Pamphlet] 2025. http:\/\/packageinserts.bms.com\/pi\/pi_camzyos.pdf (accessed 15 January 2025)."},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Masri A, Lester SJ, Stendahl JC, et al. Long-term safety and efficacy of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy: interim results of the Pioneer-OLE study. J Am Heart Assoc 2024;13:e030607. https:\/\/doi.org\/10.1161\/JAHA.123.030607; PMID:\u00a038591260.","DOI":"10.1161\/JAHA.123.030607"},{"key":"ref31","unstructured":"Desai MY, Okushi Y, Wolski K, et al. Mavacamten-associated temporal changes in left atrial function in obstructive HCM: insights from the VALOR-HCM trial. JACC Cardiovasc Imaging 2025;18:251\u201362. https:\/\/doi.org\/10.1016\/j.jcmg.2024.08.005; PMID:\u00a039254622."},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Desai MY, Okushi Y, Gaballa A, et al. Serial changes in ventricular strain in symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten: insights from the VALOR-HCM trial. Circ Cardiovasc Imaging 2024;17:e017185. https:\/\/doi.org\/10.1161\/CIRCIMAGING.124.017185; PMID:\u00a039221824.","DOI":"10.1161\/circimaging.124.017185"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Saberi S, Cardim N, Yamani M, et al. Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis. Circulation 2021;143:606\u20138. https:\/\/doi.org\/10.1161\/circulationaha.120.052359; PMID:\u00a033190524.","DOI":"10.1161\/CIRCULATIONAHA.120.052359"},{"key":"ref34","unstructured":"Masri A, Cardoso RN, Abraham TP, et al. Effect of aficamten on cardiac structure and function in obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM CMR substudy. J Am Coll Cardiol 2024;84:1806\u201317. https:\/\/doi.org\/10.1016\/j.jacc.2024.08.015; PMID:\u00a039217563."},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Heitner SB, Jacoby D, Lester SJ, et al. Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial. Ann Intern Med 2019;170:741\u20138. https:\/\/doi.org\/10.7326\/M18-3016; PMID:\u00a031035291.","DOI":"10.7326\/m18-3016"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Desai MY, Owens A, Geske JB, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal\u00a0reduction therapy. J Am Coll Cardiol 2022;80:95\u2013108. https:\/\/doi.org\/10.1016\/j.jacc.2022.04.048; PMID:\u00a035798455.","DOI":"10.1016\/j.jacc.2022.04.048"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Desai MY, Owens A, Wolski K, et al. Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial. JAMA Cardiol 2023;8:968\u201377. https:\/\/doi.org\/10.1001\/jamacardio.2023.3342; PMID:\u00a037639243.","DOI":"10.1001\/jamacardio.2023.3342"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Garcia-Pavia P, Or\u0119ziak A, Masri A, et al. Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy. Eur Heart J 2024;45:5071\u201383. https:\/\/doi.org\/10.1093\/eurheartj\/ehae579; PMID:\u00a039217450.","DOI":"10.1093\/eurheartj\/ehae579"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"McGurk KA, Bilgehan N, Ware JS. Pharmacogenetic influences over mavacamten pharmacokinetics: considerations for the treatment of individuals with hypertrophic cardiomyopathy. Circulation 2024;149:1786\u20138. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.066916; PMID:\u00a038829931.","DOI":"10.1161\/circulationaha.123.066916"},{"key":"ref40","unstructured":"Bende G, Zheng N, Wang YH, et al. Center for Drug Evaluation and Research. Application number: 214998Orig1s000. Clinical pharmacology review: mavacamten. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/214998Orig1s000ClinPharmR.pdf (accessed 17 February 2025)."},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Desai MY, Seto D, Cheung M, et al. Mavacamten: real-world experience from 22 months of the risk evaluation and mitigation strategy (REMS) program. Circ Heart Fail 2025;18:e012441. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.124.012441; PMID:\u00a039523955.","DOI":"10.1161\/circheartfailure.124.012441"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Rowin EJ, Link MS, Maron MS, Maron BJ. Evolving contemporary management of atrial fibrillation in hypertrophic cardiomyopathy. Circulation 2023;148:1797\u2013811. https:\/\/doi.org\/10.1161\/circulationaha.123.065037; PMID:\u00a038011245.","DOI":"10.1161\/circulationaha.123.065037"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Masri A, Lakdawala NK. Stop dreaming: mavacamten REMS data are here. Circ Heart Fail 2025;18:e012545. https:\/\/doi.org\/10.1161\/circheartfailure.124.012545; PMID:\u00a039523953.","DOI":"10.1161\/circheartfailure.124.012545"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Chuang C, Collibee S, Ashcraft L, et al. Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy. J Med Chem 2021;64:14142\u201352. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01290; PMID:\u00a034606259.","DOI":"10.1021\/acs.jmedchem.1c01290"},{"key":"ref45","unstructured":"Maron MS, Masri A, Nassif ME, et al. Impact of aficamten on disease and symptom burden in obstructive hypertrophic cardiomyopathy: results from SEQUOIA-HCM. J Am Coll Cardiol 2024;84:1821\u201331. https:\/\/doi.org\/10.1016\/j.jacc.2024.09.003; PMID:\u00a039352339."},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Masri A, Barriales-Villa R, Elliott P, et al. Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: a 36-week analysis from FOREST-HCM. Eur J Heart Fail 2024;26:1993\u20138. https:\/\/doi.org\/10.1002\/ejhf.3372; PMID:\u00a039023326.","DOI":"10.1002\/ejhf.3372"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Ho CY, Mealiffe ME, Bach RG, et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2020;75:2649\u201360. https:\/\/doi.org\/10.1016\/j.jacc.2020.03.064; PMID:\u00a032466879.","DOI":"10.1016\/j.jacc.2020.03.064"},{"key":"ref48","unstructured":"European Medicines Agency. Annex I: summary of product characteristics. [Camyzos pamphlet] 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/camzyos-epar-product-information_en.pdf (accessed 17 February 2025)."},{"key":"ref49","unstructured":"Reuters. FDA approves Bristol Myers\u2019 oral heart disease drug. 2022. https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/fda-approves-bristol-myers-heart-disease-drug-2022-04-29\/ (accessed 18 December 2024)."},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Del Rio CL, Rupert C, Tolley J, et al. Abstract 15612: EDG-7500, a novel cardiac sarcomere regulator that preserves intrinsic myosin-motor function, improves cardiac function and reserve in a minipig model of hypertrophic cardiomyopathy. Circulation 2023;148(Suppl 1):A15612. https:\/\/doi.org\/10.1161\/circ.148.suppl_1.15612.","DOI":"10.1161\/circ.148.suppl_1.15612"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Emter C, Lehman S, Lee L, et al. Abstract 4142919: chronic administration of EDG-7500, a novel sarcomere modulator, prevents increases in cardiac mass, T1 relaxation time, and left ventricular end diastolic pressure in a Yucat\u00e1n mini-pig model of genetic non-obstructive hypertrophic cardiomyopathy. Circulation 2024;150(Suppl 1):A4142919. https:\/\/doi.org\/10.1161\/circ.150.suppl_1.4142919.","DOI":"10.1161\/circ.150.suppl_1.4142919"},{"key":"ref52","unstructured":"Kaplan JL, Lehman S, Duvall M, et al. EDG-7500 (EDG-002), A first-in-class targeted sarcomere regulator that preserves intrinsic myosin-motor function, normalizes systolic function and eliminates LVOT obstruction in cats with hypertrophic cardiomyopathy. Presented at: American College of Cardiology (ACC) 72nd Annual Scientific Sessions, New Orleans, Louisiana, 4\u20136 March 2023. Poster 1066-13."},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Evanchik M, Emter C, Del Rio C, et al. Abstract We094: acute administration of the novel cardiac sarcomere modulator EDG-7500, improves ventricular filling while preserving LVEF in dogs with pacing induced left-ventricular systolic dysfunction. Circ Res 2024;135(Suppl 1):AWe094. https:\/\/doi.org\/10.1161\/res.135.suppl_1.We094.","DOI":"10.1161\/res.135.suppl_1.We094"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Dufton C, Evanchik M, Daniel DD, et al. EDG-7500, a first-in-class cardiac sarcomere modulator, demonstrates favorable tolerability, safety, and pharmacokinetics in healthy adults. J Card Fail 2025;31:345. https:\/\/doi.org\/10.1016\/j.cardfail.2024.10.419.","DOI":"10.1016\/j.cardfail.2024.10.419"},{"key":"ref55","unstructured":"Koch K, Evanchik M, Owens A, Semigran M. EGD-7500: phase 1 & phase 2 CIRRUS-HCM development program update. 2024. https:\/\/s204.q4cdn.com\/663829792\/files\/doc_presentations\/2024\/09\/EDG-7500-HV-and-CIRRUS-Part-A-Disclosure_vFinal.pdf (accessed 17 February 2025)."},{"key":"ref56","unstructured":"Dufton C, Evanchik M, Emery L, et al. CIRRUS-HCM: an open-label study to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic effects of EDG-7500 in adults with hypertrophic cardiomyopathy. Presented at: HFSA Annual Scientific Meeting, Atlanta, Georgia, 27\u201330 September 2024."},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 2021;384:129\u201339. https:\/\/doi.org\/10.1056\/NEJMoa2030186; PMID:\u00a033200891.","DOI":"10.1056\/NEJMoa2030186"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Zhao M, Li N, Zhou H. SGLT1: a potential drug target for cardiovascular disease. Drug Des Devel Ther 2023;17:2011\u201323. https:\/\/doi.org\/10.2147\/DDDT.S418321; PMID:\u00a037435096.","DOI":"10.2147\/DDDT.S418321"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci 2020;5:632\u201344. https:\/\/doi.org\/10.1016\/j.jacbts.2020.02.004; PMID:\u00a032613148.","DOI":"10.1016\/j.jacbts.2020.02.004"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Sacchetto C, Sequeira V, Bertero E, et al. Metabolic alterations in inherited cardiomyopathies. J Clin Med 2019;8:2195. https:\/\/doi.org\/10.3390\/jcm8122195; PMID:\u00a031842377.","DOI":"10.3390\/jcm8122195"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Li Y, Xu G. Sodium glucose cotransporter 1 (SGLT1) inhibitors in cardiovascular protection: mechanism progresses and challenges. Pharmacol Res 2022;176:106049. https:\/\/doi.org\/10.1016\/j.phrs.2021.106049; PMID:\u00a034971725.","DOI":"10.1016\/j.phrs.2021.106049"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Sherratt SC, Weindorf AV, Libby P, et al. Abstract 16947: sotagliflozin, a dual SGLT 1 and 2 inhibitor, has high membrane affinity and hydrocarbon core location compared with empagliflozin. Circulation 2023;148(Suppl 1):A16947. https:\/\/doi.org\/10.1161\/circ.148.suppl_1.16947.","DOI":"10.1161\/circ.148.suppl_1.16947"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Lin H, Guan L, Meng L, et al. SGLT1 knockdown attenuates cardiac fibroblast activation in diabetic cardiac fibrosis. Front Pharmacol 2021;12:700366. https:\/\/doi.org\/10.3389\/fphar.2021.700366; PMID:\u00a034248645.","DOI":"10.3389\/fphar.2021.700366"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Greer-Short A, Greenwood A, Leon EC, et al. AAV9-mediated MYBPC3 gene therapy with optimized expression cassette enhances cardiac function and survival in MYBPC3 cardiomyopathy models. Nat Commun 2025;16:2196. https:\/\/doi.org\/10.1038\/s41467-025-57481-7; PMID:\u00a040038304.","DOI":"10.1038\/s41467-025-57481-7"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Baka T, Moore J, Qin F, et al. Abstract 15515: SGLT2 inhibitor empagliflozin increases fatty acid oxidation, coupling between glycolysis and glucose oxidation, and decreases left ventricular hypertrophy in mice with hypertrophic cardiomyopathy due to myosin R403Q mutation. Circulation 2023;148(Suppl 1):A15515. https:\/\/doi.org\/10.1161\/circ.148.suppl_1.15515.","DOI":"10.1161\/circ.148.suppl_1.15515"},{"key":"ref66","unstructured":"Tenaya Therapeutics, Inc. Tenaya therapeutics reports promising early data from MyPEAK\u2122-1 Phase 1b\/2 clinical trial of TN-201 for treatment of MYBPC3-associated hypertrophic cardiomyopathy. 2024. https:\/\/investors.tenayatherapeutics.com\/news-releases\/news-release-details\/tenaya-therapeutics-reports-promising-early-data-mypeaktm-1\/ (accessed 18 February 2025)."},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Reichart D, Newby GA, Wakimoto H, et al. Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice. Nat Med 2023;29:412\u201321. https:\/\/doi.org\/10.1038\/s41591-022-02190-7; PMID:\u00a036797483.","DOI":"10.1038\/s41591-022-02190-7"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Nie J, Han Y, Jin Z, et al. Homology-directed repair of an MYBPC3 gene mutation in a rat model of hypertrophic cardiomyopathy. Gene Ther 2023;30:520\u20137. https:\/\/doi.org\/10.1038\/s41434-023-00384-3; PMID:\u00a036765144.","DOI":"10.1038\/s41434-023-00384-3"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Chai AC, Cui M, Chemello F, et al. Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice. Nat Med 2023;29:401\u201311. https:\/\/doi.org\/10.1038\/s41591-022-02176-5; PMID:\u00a036797478.","DOI":"10.1038\/s41591-022-02176-5"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Strong A. CRISPR gene editing therapies for hypertrophic cardiomyopathy. Nat Med 2023;29:305\u20136. https:\/\/doi.org\/10.1038\/s41591-022-02184-5; PMID:\u00a036797479.","DOI":"10.1038\/s41591-022-02184-5"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Lek A, Wong B, Keeler A, et al. Death after high-dose rAAV9 gene therapy in a patient with Duchenne\u2019s muscular dystrophy. N Engl J Med 2023;389:1203\u201310. https:\/\/doi.org\/10.1056\/NEJMoa2307798; PMID:\u00a037754285.","DOI":"10.1056\/NEJMc2312288"},{"key":"ref72","unstructured":"Maurizi N, Antiochos P, Owens A, et al. Long-term outcomes after septal reduction therapies in obstructive hypertrophic cardiomyopathy: insights from the SHARE Registry. Circulation 2024;150:1377\u201390. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.069378; PMID:\u00a039355918."},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Maron MS, Rastegar H, Dolan N, et al. Outcomes over follow-up \u226510 years after surgical myectomy for symptomatic obstructive hypertrophic cardiomyopathy. Am J Cardiol 2022;163:91\u20137. https:\/\/doi.org\/10.1016\/j.amjcard.2021.09.040; PMID:\u00a034785034.","DOI":"10.1016\/j.amjcard.2021.09.040"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Osman M, Kheiri B, Osman K, et al. Alcohol septal ablation vs myectomy for symptomatic hypertrophic obstructive cardiomyopathy: systematic review and meta-analysis. Clin Cardiol 2019;42:190\u20137. https:\/\/doi.org\/10.1002\/clc.23113; PMID:\u00a030421437.","DOI":"10.1002\/clc.23113"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Singh K, Qutub M, Carson K, et al. A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy. Catheter Cardiovasc Interv 2016;88:107\u201315. https:\/\/doi.org\/10.1002\/ccd.26293; PMID:\u00a026526299.","DOI":"10.1002\/ccd.26293"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Sorajja P, Valeti U, Nishimura RA, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2008;118:131\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.738740; PMID:\u00a018591440.","DOI":"10.1161\/CIRCULATIONAHA.107.738740"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Veselka J, Jensen MK, Liebregts M, et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Eur Heart J 2016;37:1517\u201323. https:\/\/doi.org\/10.1093\/eurheartj\/ehv693; PMID:\u00a026746632.","DOI":"10.1093\/eurheartj\/ehv693"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Minakata K, Dearani JA, Nishimura RA, et al. Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae. J Thorac Cardiovasc Surg 2004;127:481\u20139. https:\/\/doi.org\/10.1016\/j.jtcvs.2003.09.040; PMID:\u00a014762358.","DOI":"10.1016\/j.jtcvs.2003.09.040"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Hong JH, Schaff HV, Nishimura RA, et al. Mitral regurgitation in patients with hypertrophic obstructive cardiomyopathy: implications for concomitant valve procedures. J Am Coll Cardiol 2016;68:1497\u2013504. https:\/\/doi.org\/10.1016\/j.jacc.2016.07.735; PMID:\u00a027687190.","DOI":"10.1016\/j.jacc.2016.07.735"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Teo EP, Teoh JG, Hung J. Mitral valve and papillary muscle abnormalities in hypertrophic obstructive cardiomyopathy. Curr Opin Cardiol 2015;30:475\u201382. https:\/\/doi.org\/10.1097\/HCO.0000000000000200; PMID:\u00a026192489.","DOI":"10.1097\/HCO.0000000000000200"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Di Tommaso L, Stassano P, Mannacio V, et al. Asymmetric septal hypertrophy in patients with severe aortic stenosis: the usefulness of associated septal myectomy. J Thorac Cardiovasc Surg 2013;145:171\u20135. https:\/\/doi.org\/10.1016\/j.jtcvs.2011.10.096; PMID:\u00a022341422.","DOI":"10.1016\/j.jtcvs.2011.10.096"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Kayalar N, Schaff HV, Daly RC, et al. Concomitant septal myectomy at the time of aortic valve replacement for severe aortic stenosis. Ann Thorac Surg 2010;89:459\u201364. https:\/\/doi.org\/10.1016\/j.athoracsur.2009.10.065; PMID:\u00a020103321.","DOI":"10.1016\/j.athoracsur.2009.10.065"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Imori Y, Takano H, Kitamura M, et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy through non-left anterior descending septal perforators. Heart Vessels 2020;35:647\u201354. https:\/\/doi.org\/10.1007\/s00380-019-01525-8; PMID:\u00a031641886.","DOI":"10.1007\/s00380-019-01525-8"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Liebregts M, Vriesendorp PA, Mahmoodi BK, et al. A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy. JACC Heart Fail 2015;3:896\u2013905. https:\/\/doi.org\/10.1016\/j.jchf.2015.06.011; PMID:\u00a026454847.","DOI":"10.1016\/j.jchf.2015.06.011"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Sorajja P, Binder J, Nishimura RA, et al. Predictors of an optimal clinical outcome with alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Catheter Cardiovasc Interv 2013;81:E58\u201367. https:\/\/doi.org\/10.1002\/ccd.24328; PMID:\u00a022511295.","DOI":"10.1002\/ccd.24328"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Gragnano F, Pelliccia F, Guarnaccia N, et al. Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: a contemporary perspective. J Clin Med 2023;12:2810. https:\/\/doi.org\/10.3390\/jcm12082810; PMID:\u00a037109147.","DOI":"10.3390\/jcm12082810"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Agarwal S, Tuzcu EM, Desai MY, et al. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J Am Coll Cardiol 2010;55:823\u201334. https:\/\/doi.org\/10.1016\/j.jacc.2009.09.047; PMID:\u00a020170823.","DOI":"10.1016\/j.jacc.2009.09.047"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Hughes RK, Knott KD, Malcolmson J, et al. Apical hypertrophic cardiomyopathy: the variant less known. J Am Heart Assoc 2020;9:e015294. https:\/\/doi.org\/10.1161\/JAHA.119.015294; PMID:\u00a032106746.","DOI":"10.1161\/jaha.119.015294"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Canzi CC, do Prado J\u00fanior ER, da Silva Menezes J\u00fanior A, et al. Radiofrequency ablation in patients with obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis. Am Heart J Plus 2022;24:100229. https:\/\/doi.org\/10.1016\/j.ahjo.2022.100229; PMID:\u00a038560638.","DOI":"10.1016\/j.ahjo.2022.100229"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Yang H, Yang Y, Xue Y, Luo S. Efficacy and safety of radiofrequency ablation for hypertrophic obstructive cardiomyopathy: a systematic review and meta-analysis. Clin Cardiol 2020;43:450\u20138. https:\/\/doi.org\/10.1002\/clc.23341; PMID:\u00a032034788.","DOI":"10.1002\/clc.23341"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Crossen K, Jones M, Erikson C. Radiofrequency septal reduction in symptomatic hypertrophic obstructive cardiomyopathy. Heart Rhythm 2016;13:1885\u201390. https:\/\/doi.org\/10.1016\/j.hrthm.2016.04.018; PMID:\u00a027132152.","DOI":"10.1016\/j.hrthm.2016.04.018"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Zhou M, Ta S, Hahn RT, et al. Percutaneous intramyocardial septal radiofrequency ablation in patients with drug-refractory hypertrophic obstructive cardiomyopathy. JAMA Cardiol 2022;7:529\u201338. https:\/\/doi.org\/10.1001\/jamacardio.2022.0259; PMID:\u00a035353129.","DOI":"10.1001\/jamacardio.2022.0259"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Xie X, Chen S, Cui Y, et al. Midterm outcomes of percutaneous intramyocardial septal radiofrequency ablation for hypertrophic cardiomyopathy: a single-center, observational study. J Am Heart Assoc 2024;13:e034080. https:\/\/doi.org\/10.1161\/jaha.123.034080; PMID:\u00a039056345.","DOI":"10.1161\/JAHA.123.034080"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Liu Q, Qiu H, Jiang R, et al. Selective interventricular septal radiofrequency ablation in patients with hypertrophic obstructive cardiomyopathy: who can benefit? Front Cardiovasc Med 2021;8:743044. https:\/\/doi.org\/10.3389\/fcvm.2021.743044; PMID:\u00a034869646.","DOI":"10.3389\/fcvm.2021.743044"},{"key":"ref95","unstructured":"Liu L, Li J, Zuo L, et al. Percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2018;72:1898\u2013909. https:\/\/doi.org\/10.1016\/j.jacc.2018.07.080; PMID:\u00a030309466."},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"Lawrenz T, Borchert B, Leuner C, et al. Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy: acute results and 6 months\u2019 follow-up in 19 patients. J Am Coll Cardiol 2011;57:572\u20136. https:\/\/doi.org\/10.1016\/j.jacc.2010.07.055; PMID:\u00a021272748.","DOI":"10.1016\/j.jacc.2010.07.055"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"Kong L, Zhao Y, Pan H, et al. A modified endocardial radiofrequency ablation approach for hypertrophic obstructive cardiomyopathy guided by transthoracic echocardiography: a case series. Ann Transl Med 2021;9:1006. https:\/\/doi.org\/10.21037\/atm-21-2783; PMID:\u00a034277806.","DOI":"10.21037\/atm-21-2783"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"Cooper RM, Shahzad A, Hasleton J, et al. Radiofrequency ablation of the interventricular septum to treat outflow tract gradients in hypertrophic obstructive cardiomyopathy: a novel use of CARTOSound\u00ae technology to guide ablation. Europace 2016;18:113\u201320. https:\/\/doi.org\/10.1093\/europace\/euv302; PMID:\u00a026541709.","DOI":"10.1093\/europace\/euv302"},{"key":"ref99","doi-asserted-by":"publisher","unstructured":"Lawrenz T, Lawin D, Radke K, Stellbrink C. Acute and chronic effects of endocardial radiofrequency ablation of septal hypertrophy in HOCM. J Cardiovasc Electrophysiol 2021;32:2617\u201324. https:\/\/doi.org\/10.1111\/jce.15203; PMID:\u00a034379341.","DOI":"10.1111\/jce.15203"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"Jiang T, Huang B, Huo S, et al. Endocardial radiofrequency ablation vs. septal myectomy in patients with hypertrophic obstructive cardiomyopathy: a systematic review and meta-analysis. Front Surg 2022;9:859205. https:\/\/doi.org\/10.3389\/fsurg.2022.859205; PMID:\u00a035558385.","DOI":"10.3389\/fsurg.2022.859205"},{"key":"ref101","doi-asserted-by":"publisher","unstructured":"Greenbaum AB, Khan JM, Bruce CG, et al. Transcatheter myotomy to treat hypertrophic cardiomyopathy and enable transcatheter mitral valve replacement; first-in-human report of SESAME (SEptal Scoring Along the Midline Endocardium). Circ Cardiovasc Interv 2022;15:e012106. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.122.012106; PMID:\u00a035603621.","DOI":"10.1161\/circinterventions.122.012106"},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"Greenbaum AB, Ueyama HA, Gleason PT, et al. Transcatheter myotomy to reduce left ventricular outflow obstruction. J Am Coll Cardiol 2024;83:1257\u201372. https:\/\/doi.org\/10.1016\/j.jacc.2024.02.007; PMID:\u00a038471643.","DOI":"10.1016\/j.jacc.2024.02.007"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"Khan JM, Bruce CG, Greenbaum AB, et al. Transcatheter myotomy to relieve left ventricular outflow tract obstruction: the septal scoring along the midline endocardium procedure in animals. Circ Cardiovasc Interv 2022;15:e011686. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.121.011686; PMID:\u00a035378990.","DOI":"10.1161\/CIRCINTERVENTIONS.121.011686"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"Kim LK, Swaminathan RV, Looser P, et al. Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US nationwide inpatient database, 2003\u20132011. JAMA Cardiol 2016;1:324\u201332. https:\/\/doi.org\/10.1001\/jamacardio.2016.0252; PMID:\u00a027438114.","DOI":"10.1001\/jamacardio.2016.0252"},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"Rong S, Woo K, Zhou Q, et al. Septal ablation induced by transthoracic high-intensity focused ultrasound in canines. J Am Soc Echocardiogr 2013;26:1228\u201334. https:\/\/doi.org\/10.1016\/j.echo.2013.06.020; PMID:\u00a023891126.","DOI":"10.1016\/j.echo.2013.06.020"},{"key":"ref106","doi-asserted-by":"crossref","unstructured":"Takei Y, Muratore R, Kalisz A, et al. In vitro atrial septal ablation using high-intensity focused ultrasound. J Am Soc Echocardiogr 2012;25:467\u201372. https:\/\/doi.org\/10.1016\/j.echo.2011.12.010; PMID:\u00a022244000.","DOI":"10.1016\/j.echo.2011.12.010"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"Engel DJ, Muratore R, Hirata K, et al. Myocardial lesion formation using high-intensity focused ultrasound. J Am Soc Echocardiogr 2006;19:932\u20137. https:\/\/doi.org\/10.1016\/j.echo.2006.02.012; PMID:\u00a016825005.","DOI":"10.1016\/j.echo.2006.02.012"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"Li X, Zhu Z, Liu J, et al. Septal radioablation therapy for patients with hypertrophic obstructive cardiomyopathy: first-in-human study. Eur Heart J Open 2023;3:oead052. https:\/\/doi.org\/10.1093\/ehjopen\/oead052; PMID:\u00a037503357.","DOI":"10.1093\/ehjopen\/oead052"},{"key":"ref109","doi-asserted-by":"crossref","unstructured":"Nguyen A, Schaff HV, Hang D, et al. Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a propensity score-matched cohort. J Thorac Cardiovasc Surg 2019;157:306\u2013315.e3. https:\/\/doi.org\/10.1016\/j.jtcvs.2018.08.062; PMID:\u00a030279000.","DOI":"10.1016\/j.jtcvs.2018.08.062"}],"container-title":["Cardiac Failure Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2025.08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:22:59Z","timestamp":1762251779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2025.08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":110,"URL":"https:\/\/doi.org\/10.15420\/cfr.2025.08","relation":{},"ISSN":["2057-7559","2057-7540"],"issn-type":[{"value":"2057-7559","type":"electronic"},{"value":"2057-7540","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"article-number":"e27"}}